Myelosuppression is associated with human immunodeficiency virus (HIV) infection and may also be produced by agents used for the treatment of the disease or the treatment of its complications. Didanosine (ddl; 2',3'-dideoxyinosine) is a newer purine nucleoside that has recently become available for therapy for HIV infection. The effects of didanosine on peripheral blood counts have been retrospectively evaluated in the first 170 patients treated with this new agent in four phase I trials. Patients treated with didanosine showed statistically significant improvements in hemoglobin levels,
UMAN IMMUNODEFICIENCY virus (HIV) infec-
H tion has a variety of effects on hematopoiesis. Pancytopenia is part of its natural history.14 In addition, autoimmune thrombocytopenic purpura (AITP) affects patients infected with HIV.5 These effects of disease can be aggravated by therapy designed to treat the HIV infection. Zidovudine (ZDV), the first approved and most widely prescribed drug for the treatment of acquired immunodeficiency syndrome (AIDS), causes significant myelosuppression, especially anemia, which may require transfusion support. 6 Didanosine (ddI; 2',3'-dideoxyinosine) is a purine nucleoside analog selected for clinical development based on its in vitro activity against HIV-infected CD4 cells and monocytes and pharmacokinetic proper tie^.^,^ It is believed to act by preferentially inhibiting reverse transcriptase and interfering with the synthesis of viral DNA.9 After phosphorylation, the drug has an intracellular half-life in excess of 12 hours, allowing for less frequent dosing than the more rapidly cleared ZDV.l0 Didanosine has little if any effect on hematopoiesis in vitro at the doses that affect HIV replication.11J2 Of critical importance is how didanosine will affect this process in HIV-infected patients.
Clinical trials with this agent began in 1988 at the National Cancer Institute (NCI) and were first reported by Yarchoan et aI.l3 First approval by the US Food and Drug Administration for commercial distribution was in 1991 for patients intolerant to ZDV or with progressive HIV disease while treated with that drug.
Data through June 1990 from the first 170 patients treated with didanosine in four phase I trials have been retrospectively evaluated to address the following issues: (1) What effect would didanosine have on HIV myelosuppression? (2) If myelosuppression is ameliorated by didanosine, which groups or subgroups of patients benefit? analysis is based have been p u b l i~h e d ,~~-~~ this integrated summary of the data allows these issues to be addressed in a more definitive and focused manner.
While not the subject of this analysis, it is important to note that didanosine therapy is not without significant toxicities. These include dose-related and dose-limiting neuropathy and pancreatitis, which in the overall phase I experience occurred in 42% and 17% of patients, respectiveNo deaths due to pancreatitis were observed in this trial, but such events have been associated with didanosine treatment in other settings. Diarrhea was also encountered and could be related in part to the buffers used in the formulations to prevent degradation of didanosine in an acid environment. The adverse events observed in these phase I trials were generally self-limited, resolved with supportive care or suspension of didanosine, and did not preclude resumption of treatment with the drug. Abbreviations: BID, twice a day; TID. three times a day; QD, every day; IV, intravenously; PO, orally. logic criteria also varied between the trials. The lowest entry level for hemoglobin (Hb) was 8.5 g/dL and for granulocytes was 600/pL. Three trials required platelets of at least 80,OOO/pL, whereas one trial had no minimum platelet number requirement. Three of the four trials were dose escalation studies that included pharmacokinetic evaluation during the first weeks of treatment and all had an initial evaluation followed by a minimum 2-week wash out period of any prior retroviral therapy. The initial dose of didanosine and the schedule of administration differed between studies (Table 1) . At the NCI, BCH, and the ACTG sites (NYU and Rochester), drug was administered intravenously for the first 2 weeks and then orally using the same schedule. After the intravenous treatment phase, didanosine was administered orally at twice the dose used during the parenteral dosing period. Dose escalation was allowed for patients started at lower doses as experience was gained with higher doses. At the NED, all therapy was oral, with Median CD4 cell count/pL (range) p24 2 3 2 pg/mL (%) patients essentially treated at one of two doses (375 or 750 mg twice a day [BID]). Treatment was to be discontinued for severe or life-threatening toxicity or disease progression (development of an opportunistic infection) in all trials. Of the patients going off study, more than one-third did so due to toxicity, another one-third because of disease progression, and the remainder for a variety of reasons, including patient choice, loss to follow-up, and noncompliance.
MATERIALS AND METHODS

One
Laboratory studies were performed at baseline (start of therapy) and on a regular basis during treatment. A prebaseline or "screening" value was determined by using the last set of laboratory values obtained not less than 1 week before the start of didanosine. The median interval from "screening" to baseline was 2 weeks (range, 1 to 6 weeks). Bone marrow evaluations were not routinely performed. Abbreviation: n, number of patients for whom data are available. *Based on log ratio in pair-wise comparisons.
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Mean Granulocyte Count Over Time 14-day window, an arithmetic mean was used. The change from baseline was analyzed using the natural logarithm of the ratio of the interval (or screening value) to the baseline. Multiple log-ratios for a patient in the same interval were averaged.
Change in CD4 cell number was assessed by absolute increase and percent change in number of CD4 cells confirmed in two determinations at least 4 weeks apart. An increase of 50% over baseline and a minimum increase of 50 cells/p,L has been defined as a 5050 response, whereas an increase of 10% and 10 cells/pL is a 1010 response. ,0001
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*Based on log ratios in pair-wise comparisons.
A decrease in p24 antigen level was defined as a 50% reduction from baseline found in two consecutive observations at least 4 weeks apart for patients with baseline levels above 64 pg/mL. For patients with baseline levels between 32 pg/mL (the lower limit of detection) and 64 pg/mL, response was defined as a decrease to less than 32 pg/mL for at least 4 weeks.
Because three of these trials were phase I dose-escalation studies, patients started treatment at a wide range of doses. In addition, doses were modified on an individual basis during the course of the treatment. Based on safety data from these studies, the maximum tolerated dose of didanosine was identified as 12. All statistical analyses were performed using the Statistical Analysis Systems (SAS Institute, Cary, NC) software package. All proportions were compared using the Fisher's exact test. The log ratios were tested using the two-sided t-test to reject the null hypothesis that the log ratio was zero.
RESULTS
The vast majority of the patients were relatively young white males whose risk factor for infection was homosexual or bisexual behavior. Women and minorities were also represented ( Table 2) . About half of all patients had AIDS, three-quarters had previously been treated with ZDV and almost half had fewer than 50 CD4 cells/hL at entry. Of the 128 subjects previously treated with ZDV, 73 had discontinued that therapy due to hematologic toxicity, 21 due to lack of efficacy, and 34 for other reasons. Patient characteristics were similar at all sites except for NED, where all patients had been previously treated with ZDV and had severe disease or hematologic toxicity with or without progressive disease on that therapy.
A statistically significant decline in Hb and platelet numbers was seen in the period (median, 2 weeks; range, 1 to 6 weeks) from the initial screening evaluation to the start of didanosine therapy, whereas white blood cell (WBC) count and granulocyte numbers were unchanged ( Table 3) . These changes occurred regardless of prior therapy with ZDV, suggesting that the underlying disease process was causing progressive compromise of hematopoiesis.
Changes in hematologic values after the initiation of didanosine therapy were assessed for all patients and for cohorts of patients observed for similar periods of time. Analyses have been performed for patients treated up to 72 weeks. As early as 4 weeks after the initiation of treatment, there were small but statistically significant increases in Hb, WBC, granulocyte, and platelet numbers ( Table 4 and Fig 1) .
Patient characteristics.
Statuslchanges before the start of didanosine.
Effect of didanosine on peripheral blood counts. For personal use only. on October 22, 2017. by guest www.bloodjournal.org From These increases were maintained in some patients for as long as 36 weeks for all cell types and longer for WBC, granulocytes, and platelets. Improvements in Hb levels, W C numbers, granulocytes, and platelet counts were observed for patients with ARC or AIDS, whether or not the patients had been previously treated with ZDV, and for those with high or low baseline CD4 cell counts ( Table 5) . These changes were apparent in the high-and the low-dose groups ( Table 6 ). Of note, Hb levels improved despite the collection of up to 450 mL of blood samples during the first 6 weeks of treatment.
Because the decrease in values from screen to baseline could, at least in part, result from a regression to the mean, making the baseline artifactually low, changes in hematologic values were also compared with the levels determined for screening. Statistically significant increases in Hb, WBC, granulocyte, and platelet numbers were also observed in comparison to screening values ( Table 4) .
A longitudinal analysis of percent change in mean hematologic parameters shows that patients beginning treatment at doses greater than 12 mg/kg/d had greater percent increases in Hb, WBC, granulocyte, and platelet numbers during the first 16 weeks of treatment or longer (Fig 2) . These differences, while consistent, are not statistically significant. Effect of initial hematologic values on hematologic response to didanosine. Based on the World Health Organization (WHO) grading system,2O 134 of 142 evaluable patients (94%) had no change or improved Hb levels at 12 weeks ( Table 7) . At the initiation of didanosine treatment, 8 patients had an Hb less than 9.4 g/dL (WHO grade I1 or worse). After 12 weeks, 2 of these had normal Hb levels, 1 had not changed, and 5 were not evaluated (no data or patient off study).
One an improvement in WHO grade of at least one level, 7 showed no change, 3 had worsened, and no data were available for 6 who could not, therefore, be evaluated. In regard to platelet numbers, 151 of 153 patients (99%) had no change in or an improvement in WHO grade at 12 weeks. Only 4 had platelet counts of less than 75,OOO/kL (WHO grade I1 and 111) at the beginning of treatment. Of these, 3 had improved levels of platelets at 12 weeks and 1 was not evaluated (Table 7) .
Thus, regardless of initial hematologic status, patients showed improved levels of Hb, WBC, granulocyte, and platelet numbers after 12 weeks of treatment with didanosine. From July 1988, when these trials began, to June 1990, when the data base was closed, a total of 1,158 patient-months of didanosine therapy occurred with a median treatment duration of 8.5 months. During this time period, 18 patients (11%) had a transfusion (6 received RBC, 1 plasma, and for 11 the nature of blood products could not be specifically documented).
Of the 128 subjects previously treated with ZDV, 73 (57%) had discontinued that therapy due to hematologic toxicity. In contrast, only 2 of the 99 patients discontinuing treatment with didanosine as of June 1990 did so because of hematologic changes. One had a decrease in platelet numbers from 117,00O/pL at screening to 30,00O/~L on day 48, another a decrease in WBC from 2,7001pL to 1,9OO/kL on day 51.
Transfusion requirements during didanosine therapy.
Discontinuation of therapy due to hematologic toxicity.
Time to WHO grade 3 or 4 myelosuppression. Patients were evaluated for the appearance of significant myelosuppression by entry dose of didanosine ( I 12.5 mg/kg/d or > 12.5 mg/kg/d). Of the 44 patients who developed grade 3 or 4 myelosuppression (Hb, < 8 g/dL; WBC, < 2,OOO/kLL; granulocytes, < l,OOO/kL; or platelets, <50,0OO/pL) at any time during didanosine treatment, those treated at the higher dose levels took longer to do so than those treated at I 12.5 mg/kg/d (Fig 3) (P = .046 after adjusting for baseline CD4 value in a Cox regression model).
Time to grade 3 or 4 myelosuppression was strongly correlated with baseline CD4 cell count. In patients with more severe disease as measured by a CD4 count of less than 100/ pL, myelosuppression developed significantly sooner than those with greater numbers of CD4 cells at baseline (P = .OOl).
An increase in MCV is characteristically observed in the RBC of patients treated with ZDV. In the patients treated with didanosine, the MCV declined over time, from a mean of 95 fL at baseline to 88.6 after 24 weeks. A decrease in MCV was observed regardless of previous treatment with ZDV or whether the diagnosis was AIDS or ARC (Table 8) .
At the start of treatment, 25 subjects had MCVs 2 100 fL (mean f SD, 105.5 ? 2.9 fL). All had been previously treated with ZDV. After 12 weeks, 21 of these patients were still receiving didanosine. Of these, only 3 still had an MCV in excess of 100 fL and the mean ? SD for the group was 95.5 & 4.7 fL.
An analysis was performed to determine the time from 
Mean corpuscular volume (MCV).
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' " " - Hematologic changes and baseline CD4 count. As previously observed: the degree of anemia and leukopenia at the initiation of didanosine therapy correlated with the CD4 cell count at that time ( Table 9) .
Hematologic change, increase in CD4 count, and decrease in p24 antigen. In the majority of patients, there was an increase in CD4 cell numbers during treatment with didanosine. Patients with 50:50 and 1O:lO responses (see Materials and Methods) in CD4 cell numbers had greater increases in Hb and WBC than did nonresponders. These differences were statistically significant (Table 10) . Similarly, a decrease in p24 level (see Materials and Methods) was associated with a statistically significant increase in Hb, WBC, and platelet numbers, but not in granulocytes (Table 10 ).
DISCUSSION
Didanosine has been shown to decrease p24 antigen levels, increase CD4 cell numbers, and cause weight gain in HIV-infected patients with AIDS or ARC regardless of prior therapy with ZDV.19 In addition, treatment with didanosine has a positive impact on hematologic status in the same population. Data have been collected from four different phase I trials of didanosine to allow a detailed evaluation of the effects of this antiviral agent on hematopoiesis on HIV-infected patients.
The current analysis indicates that didanosine, at least in part, ameliorates HIV-induced myelosuppression. Before the start of didanosine, patients were administered no antiviral therapy for a minimum of 2 weeks. During this observation period, progressive anemia and thrombocytopenia were noted. However, it is impossible to unambiguously show that a regression to the mean is not responsible for the decrease from screen to baseline.
Like other patients with HIV infection, the subjects in these trials manifested myelosuppression proportional to the degree of CD4 cell count reduction. Treatment with didanosine resulted in a small but statistically significant The improvements seen in all hematologic parameters regardless of prior ZDV treatment indicate an effect on HIV-related myelosuppression and an ability to act even in the face of ZDV-induced myelotoxicity.
To examine the possibility that the differences observed are due to a regression to the mean, comparisons were made to the screening as well as the baseline values. Significant increases in Hb, WBC, granulocyte, and platelet numbers are still observed. These changes do not appear to result from the dropout of patients with advanced and/or more aggressive disease. They are evident within 4 weeks for Hb and WBC with 5 dropouts each and for platelets with 3 dropouts, and are based on intrapatient comparisons (drop outs not included).
While no significant decreases in hematologic values are seen at 1 year, conclusions regarding the long-term benefit of didanosine on hematopoiesis should be made with caution. The failure to show prolonged (52 weeks) improvements in hematologic parameters other than WBC may be due to the small numbers of subjects remaining on study (less than one-third of those entered), to myelosuppression caused by progressive HIV infection despite treatment with didanosine, or to a dropout bias in which patients remaining on treatment are those who benefit or those with good hematologic function at baseline.
During the early phase of dosing ( < 24 weeks), patients started at the higher doses of didanosine showed more marked improvements in their Hb, WBC, granulocytes, and platelets. Along the same line, the time to occurrence of myelosuppression was significantly longer for patients entered at doses greater than 12.5 mg/kg/d than for subjects started at or below that dose. These observations suggest a dose-response for the drug in regard to improved hematologic function.
Transfusion requirements appear to have been minimal
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From in this predominantly pretreated population with relatively advanced disease. Based on historical controls, it appears that didanosine has a neutral or even beneficial impact on the need for transfusion. Published data of a randomized trial comparing ZDV (250 mg every 4 hours) with placebo therapy6 showed that 31% of those treated with ZDV required RBC transfusion (21% needing multiple transfusions) compared with 11% (4% with multiple transfusions) of those receiving placebo. The median observation period in that trial was 4.5 months.
ZDV is known to cause an increase in RBC volume and anemia resulting in a requirement for transfusioa6 In most patients receiving didanosine, pre-existing macrocytosis secondary to ZDV therapy resolved. This resolution was dependent on how long before the start of didanosine ZDV had been discontinued, suggesting replacement of macrocytic cells by normal-sized erythrocytes apparently unaffected by didanosine therapy.
Patients who responded to didanosine, as defined by increased numbers of CD4 cells, or reduction in p24 antigenemia, were statistically more likely to have increases in Hb levels and WBC numbers than nonresponding subjects. Therefore, it appears there is a correlation between the drug's effect on these surrogate markers of disease and hematologic improvement. In summary, treatment with didanosine ameliorates the myelosuppression of HIV disease. It does so whether or not there has been prior treatment with ZDV, the patient has ARC or AIDS, the baseline CD4 cell count is above or below lOO/kL, or the starting dose is greater than or 5 12.5 mg/kg/d. The effects on bone marrow function probably represent a partial reversal of the disease process. Unlike ZDV, patients treated with didanosine have RBC of normal size and no apparent increase in transfusion requirements. As predicted by preclinical models, didanosine has little or no apparent myelosuppressive activity in humans at clinically useful doses and in addition may partially reverse the marrow suppression of HIV infection.
